You are here » Home » Companies » Company Overview » Monozyme India Ltd

Monozyme India Ltd.

BSE: 522199	Sector: Health care
NSE: N.A.	ISIN Code: INE772D01028

BSE 05:30 | 01 Jan

Monozyme India Ltd

NSE 05:30 | 01 Jan

Monozyme India Ltd

Monozyme India Ltd. (MONOZYMEINDIA) - News Sector

From Apollo to Max and Fortis, how organised health care evolved in India

10.44 am | 24 Apr 2018 | Business Standard

The first fifteen years from 2000, when hospitals like Max, Fortis started services, were for the metros, the low hanging fruit. The next wave is that...
From Apollo to Max and Fortis, how organised health care evolved in India

10.44 am | 24 Apr 2018 | Business Standard

The first fifteen years from 2000, when hospitals like Max, Fortis started services, were for the metros, the low hanging fruit. The next wave is that...
Alembic Pharma gains 5% on successful USFDA inspection of Panelav facility

9.37 am | 24 Apr 2018 | Business Standard

The stock was up 5% at Rs 527 on the BSE in early morning trade after the company informed that the successful USFDA inspection at its API facility at...
Unichem Labs up 9% as USFDA completes Ghaziabad plant with no observations

9.30 am | 23 Apr 2018 | Business Standard

The stock surged 9% to Rs 283 after the company said it has not received any observations from the US health regulator following completion of inspect...
Proxy adviser slams Fortis Healthcare board for rebuffing competing offers

11.32 pm | 20 Apr 2018 | Bloomberg

The hospital operator formed an expert panel to evaluate the proposals and make a final recommendation by April 26, when the board will make a decisio...
Radiant Life Care seeks more time from Fortis Healthcare for binding offer

11.04 pm | 20 Apr 2018 | Business Standard

With Fortis board deciding that it would only consider binding bids in its April 26 meeting, Radiant's offer might not be taken up for approval
As part of $4.2-bn global deal, P&G to acquire Merck India for Rs 12.9 bn

1.59 am | 20 Apr 2018 | Business Standard

Deal part of its $4.2 billion global acquisition of German drug maker's consumer health business
Fortis board approves evaluation of binding offers, forms expert panel

5.55 pm | 19 Apr 2018 | Press Trust of India

The committee, which will be chaired by PwC India's former chairman and CEO Deepak Kapoor, will oversee the evaluation process and give its recommenda...
Fortis Healhcare board to meet today as fresh bids continue to come in

1.04 pm | 19 Apr 2018 | Business Standard

Fortis informed BSE that the board of directors of the company had received an unsolicited non-binding expression of interest from IHH Healthcare Berh...
Merck zooms 19% on open offer by Procter & Gamble Overseas India

10.19 am | 19 Apr 2018 | Business Standard

The stock surged 19% to Rs 1,795, also its record high on the BSE after the Procter & Gamble Overseas India makes mandatory open offer at price of Rs...
Torrent Pharmaceuticals draws up plan to reduce dependence on US

10.13 pm | 18 Apr 2018 | Business Standard

Company to draw 47% of revenue and 67% of Ebitda from Indian business by FY20
Glaxo, Novartis join Bill Gates led push to fight drug-resistant Malaria

9.22 pm | 18 Apr 2018 | Bloomberg

Novartis and the Medicines for Malaria Venture are pushing to develop an alternative to artemisinin and began testing a new anti-malaria pill in Afric...
New products, over-the-counter business to fuel Glenmark's India growth

12.19 am | 17 Apr 2018 | Business Standard

With growth of 8.6 per cent in the year ended March, Glenmark was the third-fastest among top 20 pharmaceutical companies, behind Lupin and Sanofi
Divi's stock: Pricing pressure for drug makers can lead to more outsourcing

11.23 pm | 16 Apr 2018 | Business Standard

Analysts at Motilal Oswal Securities expect Divi's earnings before interest, tax, depreciation and amortisation (Ebitda) margin to improve by 400 basi...
Fortis Board to meet this week to determine future course of action

6.18 pm | 16 Apr 2018 | Press Trust of India

The company's statement comes hours after Malaysia's IHH Healthcare said Fortis has expressed inability to engage with it over its offer to acquire th...
Hero, Dabur promoters submit joint bid to buy stake in Fortis Healthcare

10.49 am | 13 Apr 2018 | Business Standard

Propose Rs 12.5 bn investment to meet hospital's urgent financial needs
Fresh fund infusion by Munjals and Burmans may alter Fortis sale plans

2.52 am | 13 Apr 2018 | Business Standard

Speaking to Business Standard, Sunil Kant Munjal, chairman, Hero Enterprise, said they are investing in Fortis for the long term
Fortis deal heats up with IHH making a better offer; stock jumps 4%

12.03 am | 13 Apr 2018 | Business Standard

This bid comes a day after private equity major TPG-backed Manipal Hospitals tweaked its offer to soothe investor concerns
Rs 40-bn rights issue addresses concerns of Fortis shareholders: Ranjan Pai

10.32 pm | 11 Apr 2018 | Business Standard

Now there is also a plan to launch a Rs 40-billion rights issue for all shareholders after the demerger, which will help existing Fortis shareholders ...
Lupin gains on EIR from USFDA for Pithampur Unit 1

10.48 am | 6 Apr 2018 | Business Standard

At 10:41 am; the stock was trading 3% higher at Rs 808 after rallied 7% to Rs 843 on the NSE in intra-day trade